- In July 2021, The US Food and Drug Administration has accepted AstraZeneca's Biologics License Application (BLA) for tezepelumab and granted it Priority Review for the treatment of asthma (FDA). AstraZeneca Plc is developing Tezepelumab in collaboration with Amgen Inc
Frequently Asked Questions
The market is segmented based on Global Mucociliary Clearance and Dysfunction Treatment Market Segmentation, By Treatment (Medications, Surgery, Mucus Clearance Device, Others), Route of Administration (Oral, Inhalation and Others), End-Users (Hospitals, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Others) - Industry Trends and Forecast to 2032
.
The Global Mucociliary Clearance And Dysfunction Treatment Market size was valued at USD 719.02 USD Million in 2024.
The Global Mucociliary Clearance And Dysfunction Treatment Market is projected to grow at a CAGR of 1.5% during the forecast period of 2025 to 2032.
The market report covers data from the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America..
